ALPHARETTA, Ga., Feb. 13, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year 2023 on Tuesday, Feb. 20 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day.
The conference call will be hosted by Joe Woody, chief executive officer, and Michael Greiner, senior vice president and chief financial officer.
To join the live conference call, dial 877-240-5772 in the United States. A simultaneous webcast of the call and a related presentation will be accessible via the Investors section of the Avanos Medical website, https://avanos.investorroom.com/.
A replay of the conference call will be available Feb. 20 at noon ET by dialing 877-344-7529 in the United States and entering passcode 5134094. It will be available for one week. A replay of the webcast also will be accessible in the Investors section of the website, approximately one hour following the completion of the conference call.
About Avanos Medical, Inc.
Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures, and markets its recognized brands globally and holds leading market positions in multiple product categories. For more information, visit www.avanos.com and follow Avanos Medical on Twitter (@AvanosMedical), LinkedIn and Facebook.
Last Trade: | US$16.08 |
Daily Change: | -0.46 -2.78 |
Daily Volume: | 1,003,347 |
Market Cap: | US$739.040M |
November 12, 2024 November 08, 2024 September 09, 2024 July 31, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB